Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGTXNASDAQ:ELUTNASDAQ:JMACNASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$0.35+10.5%$0.47$0.31▼$2.95$21.87M1.012.51 million shs316,919 shsELUTElutia$2.17-3.1%$2.85$1.87▼$5.24$88.40M0.9648,182 shs23,329 shsJMACMaxpro Capital Acquisition$5.95-2.5%$7.24$7.50▼$19.22$79.83M0.0174,040 shs17,064 shsSGMTSagimet Biosciences$2.31+3.6%$3.57$1.73▼$7.38$70.86M2.4846,460 shs258,252 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics+10.49%-0.37%-16.83%-53.57%-82.18%ELUTElutia-3.13%-19.93%-30.23%-33.44%-24.13%JMACMaxpro Capital Acquisition+7.36%-23.75%-4.54%-42.13%+973.94%SGMTSagimet Biosciences+3.59%+11.06%-34.19%-55.41%-54.35%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGTXCognition Therapeutics2.8617 of 5 stars3.53.00.00.02.22.51.3ELUTElutia3.666 of 5 stars3.55.00.00.02.25.00.6JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ASGMTSagimet Biosciences2.4322 of 5 stars3.43.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics 3.00Buy$7.131,918.99% UpsideELUTElutia 3.00Buy$9.00314.75% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/ASGMTSagimet Biosciences 2.80Moderate Buy$22.40869.70% UpsideCurrent Analyst Ratings BreakdownLatest CGTX, ELUT, JMAC, and SGMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.003/21/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/11/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.003/7/2025ELUTElutiaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $8.002/26/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.001/27/2025CGTXCognition TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 4/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/AELUTElutia$24.38M3.63N/AN/A($1.66) per share-1.31JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/ASGMTSagimet Biosciences$2M35.43N/AN/A$3.98 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$25.79M-$0.87N/AN/AN/AN/A-150.93%-100.82%5/6/2025 (Estimated)ELUTElutia-$37.66M-$2.47N/AN/AN/A-218.72%N/A-142.61%5/8/2025 (Estimated)JMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ASGMTSagimet Biosciences-$27.88M-$1.43N/AN/AN/AN/A-23.63%-22.91%5/15/2025 (Estimated)Latest CGTX, ELUT, JMAC, and SGMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12N/AN/AN/AN/AN/A3/20/2025Q4 2024CGTXCognition Therapeutics-$0.16-$0.17-$0.01-$0.17N/AN/A3/12/2025Q4 2024SGMTSagimet Biosciences-$0.65-$0.50+$0.15-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A2.112.11ELUTElutiaN/A0.940.85JMACMaxpro Capital AcquisitionN/AN/AN/ASGMTSagimet BiosciencesN/A38.4138.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%ELUTElutia74.03%JMACMaxpro Capital Acquisition73.18%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics20.75%ELUTElutia40.80%JMACMaxpro Capital Acquisition19.27%SGMTSagimet Biosciences17.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2061.97 million32.93 millionNot OptionableELUTElutia18040.74 million20.46 millionNot OptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableSGMTSagimet Biosciences830.68 million25.28 millionOptionableCGTX, ELUT, JMAC, and SGMT HeadlinesRecent News About These CompaniesWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 14.92%April 7, 2025 | aaii.comSagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Down 15.9% in MarchApril 2, 2025 | marketbeat.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 12.37%March 31, 2025 | aaii.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from AnalystsMarch 17, 2025 | marketbeat.comSagimet Biosciences (SGMT) Expected to Announce Earnings on MondayMarch 17, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for SGMT EarningsMarch 17, 2025 | marketbeat.comSagimet Biosciences Gets Clearance To Initiate Phase 1 Study Of TVB-3567 For Treatment Of AcneMarch 13, 2025 | nasdaq.comSagimet Biosciences (NASDAQ:SGMT) Announces Earnings Results, Beats Expectations By $0.15 EPSMarch 13, 2025 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC WainwrightMarch 12, 2025 | marketbeat.comSagimet Biosciences Inc.: Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 12, 2025 | finanznachrichten.deSagimet Biosciences reports Q4 EPS (50c), consensus (63c)March 12, 2025 | markets.businessinsider.comSagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate UpdatesMarch 12, 2025 | globenewswire.comSagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567March 11, 2025 | markets.businessinsider.comSagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 11, 2025 | globenewswire.comSagimet Biosciences' Denifanstat Should Be Worth More TodayMarch 7, 2025 | seekingalpha.comIs Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?February 25, 2025 | msn.comIs Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?February 25, 2025 | msn.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 10.56%February 25, 2025 | aaii.com10 Hot Penny Stocks to Buy NowFebruary 24, 2025 | insidermonkey.comSagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy NowFebruary 22, 2025 | insidermonkey.comSagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone SymposiumFebruary 19, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGTX, ELUT, JMAC, and SGMT Company DescriptionsCognition Therapeutics NASDAQ:CGTX$0.35 +0.03 (+10.49%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.31%) As of 04/11/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Elutia NASDAQ:ELUT$2.17 -0.07 (-3.13%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$2.10 -0.07 (-3.04%) As of 04/11/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Maxpro Capital Acquisition NASDAQ:JMAC$5.94 -0.16 (-2.54%) As of 04/11/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Sagimet Biosciences NASDAQ:SGMT$2.31 +0.08 (+3.59%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$2.47 +0.16 (+6.88%) As of 04/11/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Strategies Could Be a Game-Changer for Young Investors MarketBeat Week in Review — 04/07 - 04/11 JPMorgan is a Buy, if You Can Handle The Volatility Rocket Lab Stock: Weathering the Storm, Time for a Comeback? IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead United States Steel's Crash: An Unmissable Buying Opportunity Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves Is Archer Aviation’s Stock Price Dip a Gift? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
